These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Major therapeutic advances in the treatment of metastatic melanoma]. Mateus C; Robert C Bull Cancer; 2012 Jun; 99(6):619-25. PubMed ID: 22652330 [TBL] [Abstract][Full Text] [Related]
26. [Malignant melanoma]. Schmid-Wendtner M; Wendtner CM Dtsch Med Wochenschr; 2012 Dec; 137(49):2548-50. PubMed ID: 23188634 [No Abstract] [Full Text] [Related]
27. Aflibercept, ipilimumab, and vemurafenib. Hussar DA; Au AY J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387 [No Abstract] [Full Text] [Related]
28. Fanconi syndrome induced by vemurafenib: a new renal adverse event. Denis D; Franck N; Fichel F; Levi C; Dupin N JAMA Dermatol; 2015 Apr; 151(4):453-4. PubMed ID: 25494458 [No Abstract] [Full Text] [Related]
29. Challenges ahead for companion diagnostics. Schmidt C J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588 [No Abstract] [Full Text] [Related]
30. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
31. Vemurafenib-induced DRESS. Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488 [No Abstract] [Full Text] [Related]
32. Melanoma drug wins US approval. Ledford H Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150 [No Abstract] [Full Text] [Related]
33. Lupus erythematosus-like skin eruption after vemurafenib therapy. Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748 [No Abstract] [Full Text] [Related]
34. Spindle cell squamous cell carcinoma arising from verrucous hyperplasia during BRAF inhibitor therapy for melanoma. Ziemer M; Pönitzsch I; Simon JC; Schüürmann M J Dtsch Dermatol Ges; 2015 Apr; 13(4):326-8. PubMed ID: 25761417 [No Abstract] [Full Text] [Related]
35. Eccrine squamous syringometaplasia associated with vemurafenib therapy. Story SG; Beschloss JK; Dolan CK; Thomas BC J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917 [No Abstract] [Full Text] [Related]
36. Industry makes strides in melanoma. Garber K Nat Biotechnol; 2010 Aug; 28(8):763-4. PubMed ID: 20697383 [No Abstract] [Full Text] [Related]
37. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related]
38. Vemurafenib (Zelboraf) for metastatic melanoma. Med Lett Drugs Ther; 2011 Oct; 53(1374):77-8. PubMed ID: 21959356 [No Abstract] [Full Text] [Related]
39. FDA approves new PI. Gadd C IAPAC Mon; 2006 Jun; 12(6):174. PubMed ID: 17233103 [No Abstract] [Full Text] [Related]
40. New drug for metastatic melanoma increases survival rate. Carter D Am J Nurs; 2011 Sep; 111(9):16. PubMed ID: 21865918 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]